Protein kinase inhibitors in the treatment of inflammatory and autoimmune diseases.
about
Profile of tofacitinib citrate and its potential in the treatment of moderate-to-severe chronic plaque psoriasisAddressing Therapeutic Options for Ebola Virus Infection in Current and Future OutbreaksTranscriptomic Characterization of Innate and Acquired Immune Responses in Red-Legged Partridges (Alectoris rufa): A Resource for Immunoecology and Robustness SelectionTyrosine kinase inhibitors and mesenchymal stromal cells: effects on self-renewal, commitment and functionsEffect of mesenchymal stem cells on Sjögren-like mice and the microRNA expression profiles of splenic CD4+ T cellsAnti-inflammatory effects of secondary metabolites of marine Pseudomonas sp. in human neutrophils are through inhibiting P38 MAPK, JNK, and calcium pathways.Benfotiamine attenuates inflammatory response in LPS stimulated BV-2 microglia.Anti-inflammatory effects of Hwang-Heuk-San, a traditional Korean herbal formulation, on lipopolysaccharide-stimulated murine macrophages.Comparative analysis of the human and zebrafish kinomes: focus on the development of kinase inhibitors.An introduction to biomaterial-based strategies for curbing autoimmunity.Control of macrophage 3D migration: a therapeutic challenge to limit tissue infiltration.Spleen Tyrosine Kinase Modulates Fibrous Airway Obliteration and Associated Lymphoid Neogenesis After Transplantation.Molecular recognition in chemical and biological systems.iPTMnet: Integrative Bioinformatics for Studying PTM Networks.Ibrutinib-A double-edge sword in cancer and autoimmune disorders.An integrative genomics approach identifies novel pathways that influence candidaemia susceptibility.Tyrosine kinase inhibitors of Ripk2 attenuate bacterial cell wall-mediated lipolysis, inflammation and dysglycemia.Multiple signals at the extended 8p23 locus are associated with susceptibility to systemic lupus erythematosus.Protein kinases: mechanisms and downstream targets in inflammation-mediated obesity and insulin resistance.The Pyrazolobenzothiazine Core as a New Chemotype of p38 Alpha Mitogen-Activated Protein Kinase Inhibitors.Small molecules to the rescue: Inhibition of cytokine signaling in immune-mediated diseases.Inhibition of spleen tyrosine kinase activation ameliorates inflammation, cell death, and steatosis in alcoholic liver disease.A human tissue-based functional assay platform to evaluate the immune function impact of small molecule inhibitors that target the immune system.An immunosuppressive antibody-drug conjugate.Inflammation in the spotlight-clinical relevance of genetic variants affecting nuclear factor κB and tumor necrosis factor receptor 1.Data driven polypharmacological drug design for lung cancer: analyses for targeting ALK, MET, and EGFR.Enhanced protein internalization and efficient endosomal escape using polyampholyte-modified liposomes and freeze concentration.TLR7 Engagement on Dendritic Cells Enhances Autoreactive Th17 Responses via Activation of ERK.Recognition of phosphopeptides by a dinuclear copper(ii) macrocyclic complex in a water : methanol 50 : 50 v/v solution.Enhancement of cutaneous immunity during ageing by blocking p38 MAPkinase induced inflammation.Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research-practice gaps, challenges, and insights.Whole-Genome Expression Profiling in Skin Reveals SYK As a Key Regulator of Inflammation in Experimental Epidermolysis Bullosa Acquisita.Micro - Focused Phototherapy Associated To Janus Kinase Inhibitor: A Promising Valid Therapeutic Option for Patients with Localized Vitiligo.Human Th17 Migration in Three-Dimensional Collagen Involves p38 MAPK.Macrophages and the Recovery from Acute and Chronic Inflammation.AIPpred: Sequence-Based Prediction of Anti-inflammatory Peptides Using Random Forest.A Gaussian network model study suggests that structural fluctuations are higher for inactive states than active states of protein kinases.Quantitative proteomic characterization and comparison of T helper 17 and induced regulatory T cells.Myeloid p38α signaling promotes intestinal IGF-1 production and inflammation-associated tumorigenesis.Reversing the immune ageing clock: lifestyle modifications and pharmacological interventions
P2860
Q26765028-05290FB6-A174-414E-834E-4D8858227745Q26801423-780C3DE3-605C-49A7-963F-062F229D2010Q27321049-127BDA58-B0A5-472F-93E8-2533274BDEA5Q28078946-82D0DD53-4C98-4640-AB63-CDD08B56B0BAQ33744508-F8AA01F3-8F79-4585-B8AF-AECCF961CEE8Q34634726-1CA90264-9443-43A3-A337-5628EBE43C34Q35103307-CE8F472B-0812-4CD2-87C6-D0D9F440F41BQ35876575-9A5BB648-EED0-4344-B60E-3D68DA40DDEDQ36710783-16D22F91-A268-4AFD-BF38-92B367029331Q37107172-E96192F5-6944-44F2-AC3F-9B60CC14103AQ38260573-71215910-199C-4E82-B77B-DCC0534F3054Q38296865-6801809A-E48C-4A03-8671-F79C7A18913FQ38335784-5B4DE92C-8A00-46F8-940D-61DC14D09082Q38437498-B914FF16-8A09-4A89-B943-0A5841CCCB7AQ38585329-C6D11063-0469-4B8C-B440-C730FC3B098AQ38654393-AFF0552B-2332-4828-A50B-8EAF8D4B12FCQ38796867-B4F98E32-3BFD-45BE-828F-D53CCC52609DQ38910405-B6822265-CF45-442A-92F4-C1BBB118C294Q39014996-888A7D91-8D4E-4A6B-B20D-D2941DE83335Q39058419-29C5DADB-34F4-47C5-881F-F28912F3C591Q39413866-093AF3E1-19D5-4A62-B9E2-265D3B53ADF1Q39682952-854B548A-1586-42F8-B841-8C8EDAD2761BQ40129952-1B0788CD-2453-4F07-B2D8-C6FE23B683D0Q42207099-4700083A-5521-4ACE-8574-F87857144F9FQ42344455-E0E05A7A-D318-4B54-8C83-E2372675B087Q42697768-DBBC9071-2902-46C6-8484-58EBB36CC910Q45856593-593BB3E1-419B-498B-A916-EFB7C525FA9CQ45972858-5DE2B0B6-D627-416B-97F4-F5318571CAD3Q46336819-C9DC7EDC-CE26-40B7-993E-966490CD6DFDQ47385612-9C2052D2-65CF-4581-B3BA-F20F08256304Q49315568-612D4BBE-8979-4F18-9F82-F1E95B37C36EQ50333828-0FB68CCC-5756-4CE6-B3B7-E9DFBCA3BE52Q50334614-D3E746F5-91C9-4DA6-B867-DCCB33AA63F1Q51137509-DEEF530B-4DF9-46A3-A591-1C9FBCFC4D06Q51270292-8725DB04-9679-4F14-9E0D-0B3C3E5D4BE8Q52595216-5002D66B-3E50-43B0-B5DE-314DE8885D8AQ53624405-2461FE55-265C-4320-B894-DA9B3FCA0609Q55354251-4D564AEA-1826-48FC-B967-0DD67C5E7422Q55541691-61F7066E-1689-411E-BB45-B772E3AC0C80Q59132180-E63CD0AC-FFB1-4D71-9ED6-EBF7EA728E6C
P2860
Protein kinase inhibitors in the treatment of inflammatory and autoimmune diseases.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Protein kinase inhibitors in the treatment of inflammatory and autoimmune diseases.
@en
type
label
Protein kinase inhibitors in the treatment of inflammatory and autoimmune diseases.
@en
prefLabel
Protein kinase inhibitors in the treatment of inflammatory and autoimmune diseases.
@en
P2860
P50
P356
P1476
Protein kinase inhibitors in the treatment of inflammatory and autoimmune diseases.
@en
P2093
H Patterson
P2860
P356
10.1111/CEI.12248
P577
2014-04-01T00:00:00Z